platinum has been researched along with Chemotherapy-Induced Febrile Neutropenia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantrell, LA; Duska, LR; Garcia, C; Montemorano, L; Saks, E | 1 |
1 other study(ies) available for platinum and Chemotherapy-Induced Febrile Neutropenia
| Article | Year |
|---|---|
Cutting costs and standardizing care: Once-per-cycle complete blood count monitoring may be safe for patients undergoing platinum-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Chemotherapy-Induced Febrile Neutropenia; Endometrial Neoplasms; Female; Hospitalization; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Retrospective Studies | 2017 |